NCT00384969View on ClinicalTrials.gov

Sorafenib and RAD001 Renal Cell Carcinoma

PHASE1CompletedINTERVENTIONAL
Enrollment

21

Participants

Timeline

Start Date

October 31, 2006

Primary Completion Date

December 31, 2013

Study Completion Date

March 31, 2014

Conditions
Renal Cell Carcinoma
Interventions
DRUG

RAD001 and Sorafenib

RAD001 2.5mg to 10.0mg PO QD Sorafenib 400mg PO BID

Trial Locations (1)

94115

University of California, San Francisco, San Francisco

Sponsors

Collaborators (1)

Novartis
All Listed Sponsors
collaborator

Novartis

INDUSTRY

lead

University of California, San Francisco

OTHER